The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on February 13.
The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to a statement from the university.
Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
By Joseph Maliakan The new Bill introduced by the Union government , Viksit Bharat -…
By Joseph Maliakan Betrand Russel, plilosopher and logician was arrested in 1961 at the ripe…
Joseph Maliakan The Supreme Court of India on Thursday 27 November 2025 suggested the Union…
Joseph Maliakan Seven months of January to July 2025 , witnessed an unprecedented 334 incidents…
Muscat : Set to take place in Muscat this October, the 2025 edition of the…
Dubai: ADNOC Gas has entered into a 10-year agreement to supply liquefied natural gas (LNG)…
This website uses cookies.